The NAD+ longevity hypothesis originates from two converging lines of research: Leonard Guarente's work at MIT showing sirtuins (NAD+-dependent deacylases) regulate aging in yeast, and David Sinclair's (Harvard) 2013 Cell paper demonstrating that restoring NAD+ levels in aged mice via NMN reversed vascular aging, improved mitochondrial function, and boosted exercise capacity to levels resembling young mice. These findings launched the NMN/NR supplement industry and generated enormous public interest — but they also created a translation problem. Mouse models of NAD+ restoration have consistently shown impressive results; human trials have confirmed that precursors raise NAD+ levels; but robust human evidence for clinical longevity outcomes (muscle strength, metabolic health, cognitive function) remains early-stage.
The pathway: dietary NMN or NR → absorbed in gut → enters cells via Slc12a8 (NMN) or equilibrative nucleoside transporters (NR) → converted to NAD+ via NMNAT1/2/3 → NAD+ activates sirtuins (SIRT1–7) and PARP DNA repair enzymes → downstream effects on mitochondrial biogenesis (via SIRT1/PGC-1α), fatty acid oxidation, genomic stability, and senescence reduction. The rate-limiting enzyme in the salvage pathway is NAMPT (nicotinamide phosphoribosyltransferase) — NAMPT activity declines with age and is stimulated by caloric restriction and exercise, providing one mechanistic explanation for why diet and exercise also raise NAD+.
| Factor | NMN (Nicotinamide Mononucleotide) | NR (Nicotinamide Riboside) |
|---|---|---|
| Molecular weight | 334 Da — larger; must be cleaved to NR before entering most cells, then re-phosphorylated to NMN; some tissues (notably intestinal cells) may absorb NMN directly via the Slc12a8 transporter discovered by Iichiro Shimizu (2019) | 255 Da — smaller; crosses membranes more readily via equilibrative nucleoside transporters; does not require extracellular cleavage |
| NAD+ elevation (blood) | ~40–90% with 500–1,000mg/day in published human studies; Yoshino 2021 confirmed skeletal muscle NAD+ rise; Mills et al. 2016 (Cell Metabolism, mouse data) showed substantial tissue NAD+ increases | ~40–60% with 500–1,000mg/day; Martens 2018 confirmed blood NAD+ rise; Dollerup 2018 (Nat Commun, N=40, 2g/day) showed NAD+ rise without measurable metabolic changes in obese/insulin-resistant subjects |
| Human RCT clinical outcomes | Yoshino 2021 (N=25): improved skeletal muscle insulin sensitivity, reduced MG-core (methylglyoxal); Liao 2021 (Aging, N=80, NMN 600mg/day × 60 days in older adults): improved muscle strength and performance, reduced fatigability; Igarashi 2022 (NPJ Aging, N=42): improved gait speed, grip strength, and sleep quality in older adults | Martens 2018 (N=30): aortic stiffness reduced, systolic blood pressure –6mmHg in older adults with elevated blood pressure — a notable positive finding; Brakedal 2022 (Cell Metabolism, N=30, Parkinson's disease): raised brain NAD+; Dollerup 2018: no metabolic benefits in obese subjects despite NAD+ rise |
| Safety/tolerance | Well-tolerated through 500–1,000mg/day; no serious adverse effects in published trials; high doses (2g+) unstudied; long-term safety (>1 year) not well characterized; methylation concern: NAD+ catabolism produces methyl nicotinamide, which consumes SAM methyl groups — high-dose NAD+ supplementation may theoretically compete for methylation capacity; some practitioners recommend TMG (trimethylglycine) co-supplementation | Well-tolerated through 2,000mg/day; no serious adverse events in published trials; Dollerup 2018 used 2,000mg/day for 12 weeks without safety signals; same methylation concern applies at high doses |
| Cost per dose | Higher — NMN is more expensive to manufacture; typical supplement cost $1–2/day for 500mg | Lower — NR is less expensive; typical supplement cost $0.75–1.50/day for 500mg; NR has more established commercial history (ChromaDex/Tru Niagen) |
| Bottom line | More animal data supporting tissue-specific NAD+ elevation; growing human evidence for muscle/metabolic benefits in older adults; the Slc12a8 direct intestinal absorption pathway gives NMN a possible edge for gut-mediated bioavailability | More total human RCT data; the Martens 2018 aortic stiffness finding is the most compelling vascular outcome in any NAD+ precursor trial; may be better studied for cardiovascular aging |
Sirtuins are NAD+-dependent deacylases — they remove acetyl and acyl groups from histone and non-histone proteins, regulating gene expression, mitochondrial function, and stress responses. Seven mammalian sirtuins (SIRT1–7) require NAD+ as an obligate substrate and cofactor; as NAD+ falls with age, sirtuin activity declines proportionally. SIRT1 (nuclear/cytoplasmic) activates PGC-1α (master mitochondrial biogenesis regulator) and promotes autophagy and FOXO-mediated stress resistance. SIRT3 (mitochondrial) activates the mitochondrial antioxidant MnSOD and ATP synthase, improving mitochondrial efficiency. SIRT6 promotes DNA double-strand break repair — a central hallmark of aging. Guarente's lab (Cell 2013) showed that SIRT1 activity in mice declines with age in proportion to NAD+ fall, and that restoring NAD+ (via NMN) restored SIRT1 activity and vascular function. This is the core mechanistic logic behind NAD+ supplementation for aging.
CD38 is a multifunctional enzyme (glycohydrolase and ADP-ribosyl cyclase) that is the dominant NAD+-consuming enzyme in mammalian cells — consuming approximately 38-fold more NAD+ than PARP and over 100-fold more efficiently than sirtuins. CD38 expression increases dramatically with age, driven by the chronic low-grade inflammation ("inflammaging") that characterizes biological aging. Eduardo Chini (Mayo Clinic) demonstrated in a 2020 Cell Metabolism paper that CD38 is directly responsible for age-related NAD+ decline — genetic CD38 knockout in mice maintained youthful NAD+ levels and protected against metabolic dysfunction. This suggests that suppressing CD38 (via anti-inflammatory interventions, apigenin, quercetin, or CD38 inhibitors in development) may be at least as important as supplementing NAD+ precursors. A leaky bucket is hard to fill regardless of how fast you pour.
Lifestyle first — exercise raises NAD+ more than supplements in young people: High-intensity interval training (HIIT) and endurance exercise significantly upregulate NAMPT (the rate-limiting NAD+ biosynthesis enzyme), raising NAD+ levels comparably to low-dose NR/NMN supplementation in people under 40. Zone 2 training (see Zone 2 longevity guide) specifically increases mitochondrial NAD+ utilization efficiency. Caloric restriction, including time-restricted eating, also raises NAD+ via NAMPT upregulation. For people under 40 without metabolic disease, lifestyle interventions likely provide the majority of achievable NAD+ benefit.
NMN supplementation — best evidence for older adults with muscle/metabolic goals: 500mg/day in the morning (on an empty stomach for potentially better absorption, though food does not appear to substantially reduce efficacy). Studies showing muscle and metabolic benefits used 500–600mg/day. Going above 1,000mg/day has minimal additional NAD+ raising effect due to enzyme saturation and substantially increases methylation cofactor demand. If using high-dose NMN (>500mg/day), consider adding TMG (trimethylglycine) 500–1,000mg/day to support methyl group availability.
NR supplementation — particularly if cardiovascular aging is the focus: 500mg/day for general NAD+ support; 1,000mg/day for the aortic stiffness benefit seen in Martens 2018. NR's longer commercial track record and slightly lower cost make it a reasonable default for cardiovascular-focused NAD+ supplementation.
CD38 inhibition to protect NAD+ levels: Apigenin (parsley, chamomile, celery) or quercetin (onions, capers) as natural CD38 inhibitors — take with NMN/NR to reduce CD38-mediated NAD+ degradation. Quercetin phytosome 500mg is preferred for absorption. Reducing systemic inflammation (anti-inflammatory diet, omega-3, exercise) also reduces CD38 expression long-term.
Who benefits most from NAD+ precursor supplementation: Adults over 50 (when NAD+ decline accelerates and lifestyle alone may be insufficient); people with metabolic syndrome or insulin resistance; people who cannot exercise vigorously due to injury or illness; people with a personal or family history of early cardiovascular disease or neurodegenerative disease. Healthy exercising adults under 40 have less to gain from supplementation specifically.
Related comparison: NMN vs NR for NAD+ support: bioavailability, trial evidence, and price compared.
A 28-day fillable sleep log built around the seven levers that actually move sleep, so you test one per week and see what it did.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.